Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging

Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging

The SARS-CoV-2 pandemic has had a disastrous impact on global health. Although some vaccine candidates have been effective in combating SARS-CoV-2, logistical, economical, and sociological aspects still limit vaccine access globally. Recently, we reported on two room-temperature stable AAV-based COV...

Full description

Bibliographic Details
Main Authors:	Bhatt, U. (Author), Chauhan, R. (Author), Diop, C. (Author), Estelien, R. (Author), Li, D. (Author), Maciorowski, D. (Author), Vandenberghe, L.H (Author), Zabaleta, N. (Author)
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Subjects:	AAV adeno-associated virus aged Aged aging Aging animal animal model Animals Antibodies, Neutralizing Antibodies, Viral coronavirus spike glycoprotein COVID-19 COVID-19 Vaccines disease model Disease Models, Animal genetic vaccine human Humans Mice mouse neutralizing antibody obesity Obesity prevention and control SARS-CoV-2 Spike Glycoprotein, Coronavirus spike protein, SARS-CoV-2 vaccine Vaccines virus antibody
Online Access:	View Fulltext in Publisher

Similar Items

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
by: Andrabi, R., et al.
Published: (2022)

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
by: Amoako, D.G, et al.
Published: (2022)

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
by: Amoako, D.G, et al.
Published: (2022)

Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody
by: Li, Q.-L, et al.
Published: (2022)

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
by: Etienne Brochot, et al.
Published: (2020-10-01)

Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
by: Chen, B., et al.
Published: (2022)

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
by: Sai Priya Anand, et al.
Published: (2021-06-01)

Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
by: Maxwell T. Finkelstein, et al.
Published: (2021-01-01)

Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses
by: Luca Vangelista, et al.
Published: (2020-09-01)

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
by: Thomas P. Thomopoulos, et al.
Published: (2021-09-01)

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
by: Bo Meng, et al.
Published: (2021-06-01)

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2
by: Rocktotpal Konwarh, et al.
Published: (2020-06-01)

Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
by: Xia Feng, et al.
Published: (2021-03-01)

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
by: Mehul S. Suthar, et al.
Published: (2020-06-01)

A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds
by: Lara Schöler, et al.
Published: (2020-10-01)

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
by: Taufik Momin, et al.
Published: (2021-08-01)

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
by: Vikram Srivastava, et al.
Published: (2021-03-01)

Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains
by: Ki-Back Chu, et al.
Published: (2021-08-01)

Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies
by: Zach Troyer, et al.
Published: (2021-06-01)

Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
by: Efi Makdasi, et al.
Published: (2021-03-01)

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
by: Daniel Martínez-Flores, et al.
Published: (2021-07-01)

A method for the generation of pseudovirus particles bearing SARS coronavirus spike protein in high yields
by: Amano, M., et al.
Published: (2022)

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
by: Federico Gobbi, et al.
Published: (2021-03-01)

The immune system view of the coronavirus SARS-CoV-2
by: Ivana Celardo, et al.
Published: (2020-12-01)

Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
by: Arora, R.K, et al.
Published: (2022)

COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response
by: Swati Jain, et al.
Published: (2020-11-01)

An Effective COVID-19 Vaccine Needs to Engage T Cells
by: Karsten Sauer, et al.
Published: (2020-09-01)

The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic
by: Priyanka Shah, et al.
Published: (2021-03-01)

Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
by: Jie Hu, et al.
Published: (2020-12-01)

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group
by: Helena Linardou, et al.
Published: (2021-09-01)

Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
by: Yongping Yang, et al.
Published: (2021-01-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization
by: Lorraine Sazgary, et al.
Published: (2021-06-01)

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
by: Yang Li, et al.
Published: (2021-03-01)

Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
by: Jean-Louis Excler, et al.
Published: (2016-08-01)

Vaccine or monoclonal therapy: which is the winning weapon against COVID-19?
by: Lorenzo Lo Muzio, et al.
Published: (2021-09-01)

SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines
by: Yuichiro J. Suzuki, et al.
Published: (2021-01-01)

Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals
by: Hyunsuh Kim, et al.
Published: (2020-11-01)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
by: Gabriele Anichini, et al.
Published: (2021-05-01)

Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study
by: Danrong Shi, et al.
Published: (2021-07-01)